DUMITRASCU, Dan, Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA, Gianluca IANIRO, Francesca Romana PONZIANI a Antonio GASBARRINI. Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, roč. 32, č. 1, s. 92-109. ISSN 1841-8724. Dostupné z: https://dx.doi.org/10.15403/jgld-4871.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Update on the Role of Rifaximin in Digestive Diseases
Autoři DUMITRASCU, Dan (garant), Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA (203 Česká republika, domácí), Gianluca IANIRO, Francesca Romana PONZIANI a Antonio GASBARRINI.
Vydání Journal of Gastrointestinal and Liver Diseases, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30219 Gastroenterology and hepatology
Stát vydavatele Rumunsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.100 v roce 2022
Kód RIV RIV/00216224:14110/23:00131030
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.15403/jgld-4871
UT WoS 000972987600016
Klíčová slova anglicky liver cirrhosis; hepatic encephalopathy; irritable bowel syndrome; diverticular disease; gut  microbiome; rifaximin-?; symptomatic uncomplicated diverticular disease
Štítky 14110811, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 21. 6. 2023 13:32.
Anotace
Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.
VytisknoutZobrazeno: 9. 7. 2024 20:33